Contrast-induced nephrotoxicity: Clinical landscape

Richard W Katzberg, C. Haller

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Over 80 million doses of iodinated intravascular contrast media (CM) were administered in the most recent tabulations of 2003, corresponding to approximately 8 million liters, making it one of the highest volume medical drugs used compared to any other pharmaceutical. The evolution of CM has focused on minimizing adverse events by eliminating ionicity, increasing hydrophilicity, lowering osmolality and increasing the number of iodine atoms per molecule. Contrast media are classified into three general categories based on their osmolality relative to blood: high osmolar (5 times or greater than blood), low osmolar (2-3 times blood) and iso-osmolar (the same as blood). All imaging modalities that employ CM, especially computerized tomography (CT), have shown rapid growth. In the last two decades, the use of CT scanning has increased by 800%. From 1979 to 2002, the number of cardiac catheterization procedures in the USA increased by 390% and in Europe from 1992 to 1999 by 112%. There is a general consensus that renal insufficiency and diabetes are major risk factors for contrast-induced nephropathy (CIN), particularly when co-existing. The US Renal Data System documents a 'relentless' increase in kidney failure, projecting a 90% increase by 2010. Diabetes affects 194 million people worldwide and the number is anticipated to increase by 75% by 2025. The unavoidable conclusion is that patient exposure and prevalence of risk factors for CIN will continue to increase.

Original languageEnglish (US)
JournalKidney International
Volume69
Issue numberSUPPL. 100
DOIs
StatePublished - 2006

Fingerprint

Contrast Media
Osmolar Concentration
Renal Insufficiency
Tomography
Cardiac Catheterization
Hydrophobic and Hydrophilic Interactions
Information Systems
Iodine
Pharmaceutical Preparations
Kidney
Growth

Keywords

  • Contrast media, classification
  • Contrast media, effects
  • Contrast nephropathy
  • Diabetic nephropathy
  • Renal insufficiency

ASJC Scopus subject areas

  • Nephrology

Cite this

Contrast-induced nephrotoxicity : Clinical landscape. / Katzberg, Richard W; Haller, C.

In: Kidney International, Vol. 69, No. SUPPL. 100, 2006.

Research output: Contribution to journalArticle

Katzberg, Richard W ; Haller, C. / Contrast-induced nephrotoxicity : Clinical landscape. In: Kidney International. 2006 ; Vol. 69, No. SUPPL. 100.
@article{63e42ef2e3e04052814e5b8055e9b406,
title = "Contrast-induced nephrotoxicity: Clinical landscape",
abstract = "Over 80 million doses of iodinated intravascular contrast media (CM) were administered in the most recent tabulations of 2003, corresponding to approximately 8 million liters, making it one of the highest volume medical drugs used compared to any other pharmaceutical. The evolution of CM has focused on minimizing adverse events by eliminating ionicity, increasing hydrophilicity, lowering osmolality and increasing the number of iodine atoms per molecule. Contrast media are classified into three general categories based on their osmolality relative to blood: high osmolar (5 times or greater than blood), low osmolar (2-3 times blood) and iso-osmolar (the same as blood). All imaging modalities that employ CM, especially computerized tomography (CT), have shown rapid growth. In the last two decades, the use of CT scanning has increased by 800{\%}. From 1979 to 2002, the number of cardiac catheterization procedures in the USA increased by 390{\%} and in Europe from 1992 to 1999 by 112{\%}. There is a general consensus that renal insufficiency and diabetes are major risk factors for contrast-induced nephropathy (CIN), particularly when co-existing. The US Renal Data System documents a 'relentless' increase in kidney failure, projecting a 90{\%} increase by 2010. Diabetes affects 194 million people worldwide and the number is anticipated to increase by 75{\%} by 2025. The unavoidable conclusion is that patient exposure and prevalence of risk factors for CIN will continue to increase.",
keywords = "Contrast media, classification, Contrast media, effects, Contrast nephropathy, Diabetic nephropathy, Renal insufficiency",
author = "Katzberg, {Richard W} and C. Haller",
year = "2006",
doi = "10.1038/sj.ki.5000366",
language = "English (US)",
volume = "69",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "SUPPL. 100",

}

TY - JOUR

T1 - Contrast-induced nephrotoxicity

T2 - Clinical landscape

AU - Katzberg, Richard W

AU - Haller, C.

PY - 2006

Y1 - 2006

N2 - Over 80 million doses of iodinated intravascular contrast media (CM) were administered in the most recent tabulations of 2003, corresponding to approximately 8 million liters, making it one of the highest volume medical drugs used compared to any other pharmaceutical. The evolution of CM has focused on minimizing adverse events by eliminating ionicity, increasing hydrophilicity, lowering osmolality and increasing the number of iodine atoms per molecule. Contrast media are classified into three general categories based on their osmolality relative to blood: high osmolar (5 times or greater than blood), low osmolar (2-3 times blood) and iso-osmolar (the same as blood). All imaging modalities that employ CM, especially computerized tomography (CT), have shown rapid growth. In the last two decades, the use of CT scanning has increased by 800%. From 1979 to 2002, the number of cardiac catheterization procedures in the USA increased by 390% and in Europe from 1992 to 1999 by 112%. There is a general consensus that renal insufficiency and diabetes are major risk factors for contrast-induced nephropathy (CIN), particularly when co-existing. The US Renal Data System documents a 'relentless' increase in kidney failure, projecting a 90% increase by 2010. Diabetes affects 194 million people worldwide and the number is anticipated to increase by 75% by 2025. The unavoidable conclusion is that patient exposure and prevalence of risk factors for CIN will continue to increase.

AB - Over 80 million doses of iodinated intravascular contrast media (CM) were administered in the most recent tabulations of 2003, corresponding to approximately 8 million liters, making it one of the highest volume medical drugs used compared to any other pharmaceutical. The evolution of CM has focused on minimizing adverse events by eliminating ionicity, increasing hydrophilicity, lowering osmolality and increasing the number of iodine atoms per molecule. Contrast media are classified into three general categories based on their osmolality relative to blood: high osmolar (5 times or greater than blood), low osmolar (2-3 times blood) and iso-osmolar (the same as blood). All imaging modalities that employ CM, especially computerized tomography (CT), have shown rapid growth. In the last two decades, the use of CT scanning has increased by 800%. From 1979 to 2002, the number of cardiac catheterization procedures in the USA increased by 390% and in Europe from 1992 to 1999 by 112%. There is a general consensus that renal insufficiency and diabetes are major risk factors for contrast-induced nephropathy (CIN), particularly when co-existing. The US Renal Data System documents a 'relentless' increase in kidney failure, projecting a 90% increase by 2010. Diabetes affects 194 million people worldwide and the number is anticipated to increase by 75% by 2025. The unavoidable conclusion is that patient exposure and prevalence of risk factors for CIN will continue to increase.

KW - Contrast media, classification

KW - Contrast media, effects

KW - Contrast nephropathy

KW - Diabetic nephropathy

KW - Renal insufficiency

UR - http://www.scopus.com/inward/record.url?scp=33646128258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646128258&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5000366

DO - 10.1038/sj.ki.5000366

M3 - Article

AN - SCOPUS:33646128258

VL - 69

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - SUPPL. 100

ER -